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absTraCT
Open Research Biopharmaceutical Intern-
ships Support (ORBIS) is an international, Hori-
zon 2020 project funded by Maria Skłodowska-
Curie Actions, Research and Innovation Staff 
Exchange (RISE) programme. Six academic 
institutions and four pharmaceutical compa-
nies from seven countries cooperate with the 
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aim to improve the preclinical pathway of medicine development through increased Research and Develop-
ment (R&D) productivity, especially focusing on processes and technologies which address the challenge 
of poor drug bioavailability. The RISE scheme supports secondments, meaning that early stage and expe-
rienced researchers are sent to consortium partner institutions to advance studies on pharmaceutical pre-
formulation, dosage forms and drug delivery systems and methods of biopharmaceutical evaluation. The 
ORBIS project enables secondees to gain news skills and develop their competences in an international and 
intersectoral environment, strengthening the human capital and knowledge synergy in the European phar-
maceutical R&D sector.
Introduction
ORBIS (Open Research Biopharmaceutical Intern-
ships Support, grant agreement no. 778051) is an 
international and intersectoral project awarded 
€2,268,000 by the European Commission under 
the Research and Innovation Staff Exchange 
(RISE) call of Marie Skłodowska-Curie Actions 
(MSCA), Horizon 2020 programme (H2020-
MSCA-RISE-2017). This four-year project was 
launched on 1st March 2018.
ORBIS (Figure 1) is one of the largest projects 
and consortia of the RISE programme, comprising 
10 beneficiaries and partners; these include six 
academic institutions and four pharmaceutical 
companies located in seven countries (Figure 2). 
This project will enable over 200 researchers to 
advance their research and other skills through 
secondment placements. Poznan University of 
Medical Sciences (PUMS, Poland) is the proj-
ect coordinator and the grant is managed by the 
project chair, Professor Janina Lulek, Head of the 
Chair and Department of Pharmaceutical Tech-
nology at PUMS.
Research Project Objectives
The current process of drug development is 
lengthy and inefficient. When developing a new 
chemical entity only one out of approximately 
10,000 molecules enters the market as a drug. 
The situation is no better for generic or value-
added medicinal products, where the active 
pharmaceutical ingredient (API) is already well-
known: commencing from the first laboratory tri-
als, it takes a minimum of four years of intensive 
activities for the simplest generic drug product to 
reach the market. The societal demand for more 
effective medicines has created a challenge of 
supply within the pharmaceutical industry. To 
address this gap, ORBIS proposes that the time 
for the medicinal product to reach the patients 
might be reduced by improving early stage R&D 
productivity. The overarching objective of ORBIS 
is to form an international and intersectoral aca-
demic and industrial network to address this 
challenge (Table 1). This consortium was built 
on pre-existing collaboration that has expand-
ed into the current ORBIS group (Figure 2). The 
project aims to improve the preclinical pathway 
of medicine development, concentrating on pro-
cesses and technologies to address poor drug 
bioavailability.
The close research cooperation between the 
project partners, as well as knowledge synergy 
and transfer between the academic and industri-
al sectors, has created a stimulating environment 
for employees and PhD students to advance their 
individual career and transferrable skills during 
research visits (ORBIS secondments) and those 
interactions are the core enablers of the consor-
tium objectives (Table 2).
Research Plan and Basic Concept
The core and vehicle for accomplishing the 
ORBIS project objectives are secondments, i.e. 1- 
to 12-month long research and training visits of 
early stage and experienced researchers at part-
ner institutions. PhD students and employees 
from the European universities can travel abroad 
Figure 1. ORBIS official logo
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to pharmaceutical companies and Rutgers Uni-
versity, while staff from the industrial members 
visit foreign academic partners, meaning that all 
secondments must be international and mostly 
intersectoral.
ORBIS activities are organized in 7 Work Pack-
ages (WP), each addressing a specific project 
objective to streamline the scientific progress, 
knowledge transfer or dissemination.
The aim of WP1: Drug substances and phar-
maceutical preformulation is to translate the dis-
covery synthesis of a drug substance (API) into 
technology development and investigate the sol-
id-state physicochemical characteristics of APIs. 
The overarching goal is to improve unfavourable 
biopharmaceutical characteristics of APIs, i.e. 
poor solubility and/or dissolution. To acceler-
ate small molecule process design, several tech-
nological platforms are explored to deliver an 
improved product better suited for further formu-
lation development. Research employs advanced 
analytical equipment to investigate the intrinsic, 
solid state and derived properties of the APIs and 
their forms.
The purpose of WP2: Dosage forms and drug 
delivery systems is to design, develop and test 
new drug carriers and dosage forms for oral and 
topical delivery of drugs. Examples of oral for-
mulations are novel liposomes, polymeric nano- 
and microparticles, minitablets, self-microemul-
Table 1. Institutions participating in ORBIS project
Institution name 
and acronym




Poznan, Poland Project beneficiary and coordinator. Apart from the project management and 
organization, several departments of Faculty of Pharmacy are engaged in sending and 
hosting secondees. PUMS expertise includes: pharmaceutical preformulation, drug 
design and delivery, physical chemistry, pharmaceutical and biopharmaceutical 
analysis, pharmacokinetics. 
APC Ltd. (APC) Dublin, Ireland Project beneficiary. APC specializes in integrating innovative process performance 
across a medicine’s life cycle, from early Phase development to manufacturing support. 
APC’s research platforms and associated information deliverables help the global bio/
pharma sector accelerate the development and launch of their medicines.
JSC Farmak (FMK) Kyiv, Ukraine Project beneficiary. FMK is the leading Ukrainian developer of generic and innovative 






Warsaw, Poland Project beneficiary. PRI develops API manufacturing technologies, translating academic 
research into practical solutions for industry. Expertise covers laboratory scale 
synthesis and scale-up, development of formulations, analytics and pharmacokinetic 





Project beneficiary. PHY develops biorelevant test methods for assessing in vitro 




Poznan, Poland Project beneficiary. Researchers of the Institute of Chemical Technology and 
Engineering, Faculty of Chemical Technology, provide knowledge in areas of inorganic 




Helsinki, Finland Project beneficiary. The Formulation and Industrial Pharmacy unit of the Division of 
Pharmaceutical Chemistry and Technology focuses on the translation of a drug 
molecule into a medicine. Expertise is offered in novel spectroscopic techniques and 
manufacturing technologies of oral solid dosage forms.
Trinity College 
Dublin (TCD)
Dublin, Ireland Project beneficiary. Trinity Pharmacy & Pharmacology is joint 45 in the world by subject 
(Pharmacy and Pharmacology) and the School of Pharmacy and Pharmaceutical 
Sciences is the leading Pharmacy educator in Ireland. The expertise includes 
pharmaceutical preformulation, engineering of solid-state materials and advanced oral 
and pulmonary formulations.  
Zentiva (ZNT) Prague, Czech 
Republic
Project beneficiary. ZNT is an international pharmaceutical company that develops, 
manufactures and distributes generic and value-added medicinal drug products for oral 
and parenteral drug delivery. 
Rutgers, the State 
University of New 
Jersey (RUTG)
New Jersey, USA Project partner. RUTG is a member of the “Big 10” top universities in the U.S. with 
70,000 undergraduates & graduates &over $750.8 million in research monies. The 
School of Pharmacy is in the top ten pharmacy schools in the US. Center for Dermal 
Research founded in 2011 is the only academic Center in NJ dedicated to 
pharmaceutical skin research.
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Table 2. ORBIS project objectives
To improve the process development of drug substances by innovating 
synthesis and evaluation of active materials and their physical forms.
To enable hands-on and relevant industrial training of 
early stage researchers including a range of “soft skills”.
To advance pharmaceutical preformulation studies by developing new 
industry-relevant methods of evaluation of drug substances physical 
forms in the biopharmaceutical context.
To foster “communal” academia-industry open 
collaboration.
To formulate advanced drug delivery systems and optimize 
manufacturing of oral dosage forms.
To support industry-academia research leading to joint 
publications, presentations and enabling staff transfer 
between these two sectors.
To better understand drug transport across the skin and develop topical 
and transdermal delivery systems.
To innovate the biopharmaceutical evaluation of dosage forms and drug 
delivery systems by improving the testing approaches and methods of 
bioanalysis.
Table 3. Overview of ORBIS summer schools and workshops
Event name Organizing institutions Place and date
1st School on pharmaceutical preformulation testing 
of APIs and dosage forms. TCD & APC
Dublin, 12–14th June 2019
Open Workshop on process development of drug 
substances. FMK
2nd ORBIS Summer School on Oral Dosage Forms: 
Fundamentals, Challenges and Future Opportunities UH & ZNT Helsinki, 18–20th 
September 2019ORBIS Workshop on Dosage Forms and Drug 
Delivery Systems. UH
3rd School on topical and transdermal drug delivery 
systems. PUMS & RUTG 
Poznan, 29th September 
– 1st October 2020
4th School on biopharmaceutical evaluation 
of dosage forms and drug delivery. ZNT & PRI 
Prague, September 2021
Open Workshop on biopharmaceutical evaluation 
of dosage forms and drug delivery systems. PHY
Figure 2. ORBIS network. Pre-ORBIS collaboration (black lines) and new ORBIS collabora-
tion (green lines). Industry partners are marked with a star
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sifying systems or mesoporous materials, while 
topical pharmaceutical dosage forms include 
liquid (ionic liquids, microemulsions), semi-solid 
(hydrogels, organogels, creams) and adhesive 
(patches). This work package employs a variety 
of advanced methods to analyse the developed 
formulations, including novel imaging and struc-
ture analysis techniques and in vitro skin perme-
ation tests.
WP3: Biopharmaceutical evaluation of dos-
age forms and drug delivery systems focuses on 
the development of biorelevant methods for in 
vitro dissolution and release testing, simulating 
conditions that act on dosage forms during their 
gastro-intestinal passage. An additional aim is 
to advance bioanalytical methods, including bio-
logical sample preparation techniques, reduc-
ing HPLC analysis time and assessing validation 
parameters according to the European Medicines 
Agency guidelines [1].
In addition to the scientific WPs, ORBIS is sup-
ported by four other WPs. WP4: Training espe-
cially concerns early stage researchers. Second-
ments are an opportunity to become familiar with 
new research topics and intersectoral environ-
ments, learn new methodologies and techniques 
as well as develop transferrable scientific and 
“soft” skills, further increasing employability of 
the young researchers. WP5: Management deals 
with the strategic management and organization 
of this large consortium, while WP6: Communi-
cation and dissemination increases the project 
impact, visibility and dissemination of results. 
WP7: Ethics monitors the handling of ethical 
issues related to the project and it is supported 
by the Honorary Ethical Advisory Board, an inde-
pendent body of external experts.
Research Methodology
Methods include API synthesis, preformula-
tion studies, manufacturing, analytics (includ-
ing bioanalytics), continuous processing, quality 
by design and new testing methodology design. 
Also, a blend of experimental and computational 
techniques is used to accomplish the research 
goals. Experts in the various research areas from 
the consortium are involved in the design of the 
methods and approaches, amalgamating the 
expertise in the multidisciplinary, international 
and intersectoral consortium. The partners are 
integrating their common research protocols and 
filling gaps in individual infrastructures.
Measurable effects and 
expected results
Several deliverables and milestones are aligned 
with the objectives of the ORBIS project. The WP1 
team will demonstrate a continuous operation of 
synthesis/crystallisation processes for APIs rel-
evant to ORBIS and develop a strategy to improve 
the solubility/permeability of BCS class II and IV 
APIs. A public report on perspectives of API man-
ufacturing and advances in preformulation stud-
ies will be jointly prepared.
The WP2 milestones comprise the demonstra-
tion of oral formulation advancements accom-
plished as a part of ORBIS (e.g. minitablets, novel 
drug carriers) and improvements in formulation 
of transdermal dosage forms. A WP2 deliver-
able will be a public report on new insights into 
oral dosage forms and delivery systems as well 
as novel approaches in topical and transdermal 
drug delivery.
The main impact of WP3 will be the success-
ful evaluation of bioanalytical methods for select-
ed APIs. The WP3 team will prepare a report on 
pharmacokinetics driven development of dosage 
form specifications and estimation of pharma-
cokinetics based on in vitro data.
To date, after 24 months of project activity, 
221 months of secondments have been complet-
ed and have started to deliver tangible research 
outputs, such as new research collaborations 
and publications [2-6].
Apart from the scientific deliverables and 
milestones, the progress of the ORBIS project 
is measured by completing activities related to 
training, management and dissemination. Four 
summer schools and workshops for ORBIS par-
ticipants are the outcomes of WP4 (Table 3). 
These events involve lectures delivered by world-
class researchers, hands-on workshops and 
demonstrations of relevant techniques, as well 
as are an opportunity to showcase the organizing 
partners’ capabilities and the results of second-
ments. The summer schools and workshops are 
also excellent networking events for strengthen-
ing the relationships and formulating new ideas 
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for cooperation between the ORBIS partners and 
reaching beyond the timeframe of this project.
To date, the project has also successfully 
achieved its managerial deliverables – including 
two out of the three major consortium meetings 
(kick-off, mid-term and planned final conference) 
and one out of the two progress reports. Proj-
ect activities and outputs can be followed on the 
ORBIS website and social media channels estab-
lished as dissemination deliverables [7].
A goal of ORBIS is to have 504 months of sec-
ondments achieved by February 2022. This will 
lead to over two hundred researchers from Euro-
pean academia and pharmaceutical companies 
gaining new skills and experience in an interna-
tional and interprofessional environment. A key 
impact of the ORBIS project will be increased 
competence and employability of researchers in 
the European pharmaceutical sector. Through 
new personal ties, academic and industrial insti-
tutions will form close cooperation and partner-
ships beyond the scope and duration of ORBIS. 
The project will enhance the transfer of knowl-
edge in the pharmaceutical sector, ultimately 
strengthening human capital in research and 
innovation under the MSCA-RISE action.
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